Clinical trial
A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With Chronic Hepatitis B Virus and Receiving or Stopping Treatment With a Nucleoside/Nucleotide Inhibitor
NCT04023721 is registered in ClinicalTrials.gov with F-star Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With Chronic Hepatitis B Virus and Receiving or Stopping Treatment With a Nucleoside/Nucleotide Inhibitor
- Lead sponsor
- F-star Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 18, 2019
- Completion date
- July 16, 2020
- Enrollment
- 64 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.